INNOGEN-B (02591) surged nearly 10%, reaching HK$31.8 by the time of writing, with a trading volume of HK$2.77 million. The uptick follows the announcement of the Hang Seng Index Series quarterly review results on November 21, with all changes taking effect from December 8, 2025. Notably, INNOGEN-B has been added to the Hang Seng Composite Index constituents.

In September this year, INNOGEN-B disclosed the completion of the first patient dosing in its Phase III clinical trial in China for its core product, Esupagrutide α, targeting obesity and overweight conditions. The trial aims to enroll approximately 800 participants.

Earlier, Shanghai Securities highlighted Esupagrutide α's strong safety profile and efficacy in glucose control and weight reduction, demonstrating significant advantages in treating chronic metabolic diseases such as diabetes, obesity, and fatty liver. The firm's listing on the Hong Kong Exchange is expected to accelerate its R&D pipeline and commercialization efforts.

With sustained interest in the GLP-1 sector and intensifying competition, attention is advised on indications expansion, regulatory filings, and commercialization progress.